Braveheart Bio to Present at Cantor Global Healthcare Conference as It Advances BHB-1893 for Hypertrophic Cardiomyopathy
核心洞察
Braveheart Bio (搜索), a clinical-stage biopharmaceutical company, will participate in the Cantor Global Healthcare Conference in New York from September 9–11, 2026, with a fireside chat on September 10.
The company's lead candidate, BHB-1893 (搜索), is a next-generation oral small-molecule cardiac myosin (搜索) inhibitor being developed for both obstructive and non-obstructive hypertrophic cardiomyopathy (搜索).
BHB-1893 (搜索) is designed to address limitations of currently available cardiac myosin (搜索) inhibitors through rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and simplified titration and monitoring.
Braveheart Bio (搜索), Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (搜索) (HCM) and other serious cardiovascular diseases, announced that it will participate in the Cantor Global Healthcare Conference, being held September 9–11 in New York, NY. Management will participate in a fireside chat on Thursday, September 10, 2026 at 3:20 p.m. EDT.
Interested parties may access a live webcast by visiting the News & Events section of the Braveheart website at https://ir.braveheart.bio/, with replays available in a temporary archive following the event.
Advancing a Next-Generation Cardiac Myosin Inhibitor
Braveheart Bio (搜索)'s lead product candidate, BHB-1893 (搜索), is a next-generation oral small-molecule cardiac myosin (搜索) inhibitor (CMI) being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
The company is aiming to address the limitations of currently available CMIs by designing BHB-1893 (搜索) for rapid onset, consistent depth of response, preservation of systolic function, prompt reversibility, and a straightforward approach to titration and monitoring.
Company Focus
Braveheart Bio (搜索) is a clinical-stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy (搜索) (HCM) and other serious cardiovascular diseases.
Investor relations inquiries may be directed to Alexander Sharif of New Street Investor Relations, with media inquiries handled by FGS Global.